Mitigation of Virulence in Resistant Escherichia Coli by Diclofenac Sodium, Phenotypic and Genotypic Study.

• DOI: 10.21608/dusj.2024.249152.1034
• Publication Date: 2024-05-25T07:33:41Z
• Authors: Sara M. Eltabey; Ali H. Ibrahim; Mahmoud M. Zaky; Moustafa M. Saleh
• Keywords: Diclofenac Sodium

Escherichia coli is one of the most ubiquitous pathogens causing several life-threatening diseases. Currently, antibiotics are failing fast while rates drug-resistant bacteria increasing worldwide with almost no new drugs coming to market and even last-resort becoming ineffective. Anti-virulence a approach targeting bacterial virulence unlike classic aimed at disarming rather than killing them or inhibiting their growth. Inactivation arsenal factors will attenuate render susceptible natural host defenses. The effect FDA-approved drug diclofenac sodium sub-inhibitory concentration (¼ MIC) on some was evaluated phenotypically genotypically. Phenotypically, biofilm formation ability, proteases production motility behavior were found be significantly decreased under sodium. Genotypically, qRT-PCR used evaluate relative expression levels papC, fimH, ompT_m, stcE flic genes regulating production. Importantly, all tested showed significant downregulation current research revealed that has promising anti-virulence against resistant coli. As result, it suggested that, in addition as an adjuvant traditional antimicrobials, could possible solution treat infections caused by